| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
No specific drug target; serves as an endogenous metabolite and biomarker for PGF2alpha production. May bind to bovine acetylcholinesterase and potentially other plasma proteins.
|
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
13,14-Dihydro-15-keto-PGF2alpha is the first prominent plasma metabolite of PGF2alpha. It is an endogenously produced metabolite present in the blood and may be utilized to study pregnancy. It has been shown to bind to bovine acetylcholinesterase. As a metabolite, it exhibits significantly reduced biological activity compared to its parent compound PGF2alpha. |
| ln Vivo |
As a metabolite, 13,14-Dihydro-15-keto-PGF2alpha is used as a biomarker to assess in vivo production of PGF2alpha. Measurement of PGFM levels in blood and urine serves as an indicator of PGF2alpha release in various physiological and pathological conditions, including pregnancy, parturition, inflammation, and reproductive disorders. Elevated levels may indicate increased PGF2alpha synthesis.
|
| Enzyme Assay |
Receptor binding assays are not applicable for this metabolite as it has low biological activity. Standard analytical protocols for measuring 13,14-Dihydro-15-keto-PGF2alpha in biological samples involve immunoassays (EIA or RIA) or LC-MS/MS. For LC-MS/MS, samples (plasma, serum, or urine) undergo solid-phase extraction, separation on a reverse-phase C18 column, and detection in negative ion mode with MRM. For EIA, kits specific for this metabolite are used.
|
| Cell Assay |
For cell-based studies, cultured endometrial, myometrial, or placental cells may be treated with PGF2alpha (1-100 nM) for 1-24 hours, and culture medium is analyzed for 13,14-Dihydro-15-keto-PGF2alpha accumulation by EIA or LC-MS/MS to assess 15-PGDH and delta¹3-reductase activity. The metabolite itself is not typically used as a treatment in cellular assays.
|
| Animal Protocol |
In vivo animal studies using this compound are typically conducted for pharmacokinetic or biomarker studies. Rodents are administered PGF2alpha (intramuscular or intravenous, 0.1-1 mg/kg), and blood samples are collected at multiple time points (0-6 hours). Plasma levels of 13,14-Dihydro-15-keto-PGF2alpha are measured by EIA or LC-MS/MS to quantify PGF2alpha clearance and metabolite formation. Alternatively, endogenous levels are measured in pregnancy models.
|
| ADME/Pharmacokinetics |
13,14-Dihydro-15-keto-PGF2alpha is a circulating metabolite that is rapidly formed from PGF2alpha following its release. The conversion occurs primarily in the lungs, liver, and kidneys via 15-PGDH (which reduces the 15-hydroxyl group to a 15-keto group) and delta¹3-reductase (which reduces the 13,14 double bond). The resulting PGFM has a longer half-life than PGF2alpha (approximately 10-20 minutes vs. 1-2 minutes), making it a more stable biomarker.
|
| Toxicity/Toxicokinetics |
As an endogenous metabolite, 13,14-Dihydro-15-keto-PGF2alpha is not toxic. It is normally present at low concentrations in healthy individuals (typically <20 pg/mL in plasma). Elevated levels reflect increased PGF2alpha production, which is associated with physiological processes (parturition, menstruation) or pathological conditions (dysmenorrhea, endometriosis, inflammation).
|
| References | |
| Additional Infomation |
13,14-Dihydro-15-keto-PGF2α is a prostaglandin Fα obtained by formal oxidation of the 15-hydroxyl group of prostaglandin F2α and hydrogenation of the 13,14-double bond. It is a metabolite. It is both a prostaglandin Fα and a ketone. Functionally, it is related to prostaglandin F2α. It is the conjugate acid of 13,14-dihydro-15-keto-PGF2α(1-).
13,14-Dihydro-15-keto-PGF2alpha (PGFM) is an endogenous metabolite and research biomarker, not a therapeutic agent. It is the stable end product of PGF2alpha metabolism and is widely used in reproductive biology research. Its measurement is used to monitor spontaneous or induced labor, to study luteolysis in animal models, and to assess PGF2alpha production in inflammatory conditions. This compound has no approved clinical indications for therapeutic use. |
| Molecular Formula |
C20H34O5
|
|---|---|
| Molecular Weight |
354.48
|
| Exact Mass |
354.24
|
| CAS # |
27376-76-7
|
| PubChem CID |
5283039
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
543.0±40.0 °C at 760 mmHg
|
| Flash Point |
296.2±23.8 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.512
|
| LogP |
2.13
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
25
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCCC(CC[C@H]1C(O)CC(O)[C@@H]1C/C=C/CCCC(=O)O)=O
|
| InChi Key |
VKTIONYPMSCHQI-XAGFEHLVSA-N
|
| InChi Code |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-19,22-23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+,19-/m1/s1
|
| Chemical Name |
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8210 mL | 14.1052 mL | 28.2103 mL | |
| 5 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL | |
| 10 mM | 0.2821 mL | 1.4105 mL | 2.8210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
